Company profile: Atalanta Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology focused on pioneering new treatment options for neurodegenerative diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atalanta Therapeutics
Lundbeck
HQ: Denmark
Website
- Description: Provider of pharmaceuticals for psychiatric and neurological disorders, engaged globally in the research, development, production, marketing, and sale of these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lundbeck company profile →
iPierian
HQ: United States
Website
- Description: Provider of a drug discovery platform leveraging induced pluripotent stem cells to discover and develop therapies for neurodegenerative diseases, including SMA, ALS, and Parkinson's, addressing other major unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iPierian company profile →
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
Algynomics
HQ: United States
Website
- Description: Provider of a research-stage pain diagnostics platform leveraging patient cohorts to deliver prospective data that identifies individuals at increased risk for chronic pain, enabling targeted preventive efforts and enhancing patient stratification in clinical trials to identify treatment responders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algynomics company profile →
IRLAB Therapeutics
HQ: Sweden
Website
- Description: Provider of drug discovery and development for brain disorders, targeting core dysfunctions in Parkinson’s disease and dementias. Offers ISP, a proprietary systems pharmacology platform built on a unique CNS compound database, and is advancing two phase II candidates: Mesdopetam (IRL790) for levodopa-induced dyskinesia and Pirepemat (IRL752) for impaired balance and reducing falls in Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IRLAB Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atalanta Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atalanta Therapeutics
2.2 - Growth funds investing in similar companies to Atalanta Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atalanta Therapeutics
4.2 - Public trading comparable groups for Atalanta Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →